Graves’ ophthalmopathy (GO) is an autoimmune disease, and there is no specific treatment drug. Glucocorticoid (GC) therapy is still the first-line therapy for patients with moderate to severe GO. Targeted therapy may become a novel treatment due to GC’s adverse drug reactions. As the in-depth study of the pathogenesis of GO, many targeted drugs with randomized clinical trial (RCT) treatment have appeared in recent years, such as anti-insulin growth factor 1 receptor (teprotumumab), anti-CD20 (rituximab) and anti-interleukin(IL)-6 receptor (tocilizumab). It is worth noting that teprotumumab has been approved by US Food and Drug Administration in recently, and may quickly become the first-line therapy for GO. The anti-B cell stimulating factor (belimumab) which is undergoing RCT is waiting for the result of RCT to reveal. Anti-tumor necrosis factor-α (such as etanercept, adalimumab, and infliximab) which only used in case reports requires RCT further verification. In addition, anti-IL-17/IL-23, thyroid stimulating hormone receptor, CD40 targets and target therapies may have potential clinical value for GO due to the successful use of these target therapies in vitro experiments and other autoimmune diseases. This paper focus on the progress of targeted therapy of GO in China and abroad in recent years.

Citation： HAI Yuanping, LIU Haiwei. Current status and progress of targeted therapy in Graves’ ophthalmopathy. West China Medical Journal, 2021, 36(10): 1444-1449. doi: 10.7507/1002-0179.202004228 Copy